The proteasome inhibitor bortezomib inhibits intimal hyperplasia of autologous vein grafting in rat model
The proteasome inhibitor bortezomib inhibits intimal hyperplasia of autologous vein grafting in rat model
复制标题
DOI：
10.1016/j.transproceed.2008.01.063
复制
发表时间：
2008-06-01
影响因子：
0.9
通讯作者：
Gu, X. H.
中科院分区：
文献类型：
--
作者：
He, X. P.;Li, X. X.;Gu, X. H.
目标。越来越多的证据表明，炎症在自体静脉移植所致的内膜增生(IH)中起重要作用。蛋白酶体抑制剂Bortezomib具有抗炎作用，因此我们使用自体静脉移植模型来测试Bortezomib是否抑制移植诱导的血管病变的新生内膜形成。材料和方法。我们对88只大鼠进行了自体颈外静脉移植手术，随机分配给硼替佐米或赋形剂治疗。24或72小时后处死大鼠，对移植静脉进行实时RT-PCR(24和72小时)、ELISA(24小时)或中性粒细胞趋化试验(24小时)。随后，在移植后1周和2周处死大鼠，并对样本进行形态计量学分析。与未经处理的对照组相比，2周时，硼替佐米显著抑制IH(P
Objective. Increasing evidence indicates that inflammation plays an important role in intimal hyperplasia (IH) induced by autologous vein grafts. The proteasome inhibitor bortezomib shows anti-inflammatory effects, so we used an autologous vein transplantation model to test whether bortezomib inhibits neointimal formation in transplant-induced vasculopathy.Materials and Methods. We subjected 88 rats to autologous external jugular vein grafting surgery randomly assigned to be treated with bortezomib or vehicle. After 24 or 72 hours, rats were humanely killed and vein grafts processed for real-time RT-PCR (24 and 72 hours), ELISA (24 hours), or neutrophil chemotaxis assay (24 hours). Subsequently, rats were humanely killed at 1 and 2 weeks after grafting with samples processed for morphometric analysis.Results. Bortezomib significantly inhibited IH at 2 weeks compared with untreated controls (P